Targeting delivery in Parkinson's disease

• Neuroprotective therapies remain an unmet need for Parkinson's disease.
• Targeting may allow delivery of neuroprotective molecules to the diseased brain.
• This has many challenges and opportunities for the therapy of Parkinson's disease.

Disease-modifying therapies for Parkinson's disease (PD), with the potential to halt the neurodegenerative process and to stimulate the protection, repair, and regeneration of dopaminergic neurons, remain a vital but unmet clinical need. Targeting the delivery of current and new therapeutics directly to the diseased brain region (in particular the nigrostriatal pathway) could result in greater improvements in the motor functions that characterise PD. Here, we highlight some of the opportunities and challenges facing the development of the next generation of therapies for patients with PD.